Literature DB >> 1442854

Tuberculous meningitis in patients with and without human immunodeficiency virus infection.

M P Dubé1, P D Holtom, R A Larsen.   

Abstract

OBJECTIVE: To characterize the symptoms, signs, laboratory findings, and outcome of culture-proven meningitis due to Mycobacterium tuberculosis in patients with and without human immunodeficiency virus (HIV) infection.
DESIGN: Retrospective chart review.
SETTING: Urban public general hospital in the United States. PATIENTS: Fifteen patients with and 16 without HIV infection. MEASUREMENTS: Demographics, symptoms, physical exam findings, serum sodium, complete blood cell count, CD4+ cell count, cerebrospinal fluid findings, imaging data, and in-hospital mortality. MAIN
RESULTS: Symptoms, signs, chest radiograph appearance, cerebrospinal fluid cell counts and chemistries, and mortality were similar in both groups (p = NS). Median CD4+ cell counts were lower in HIV-infected patients (median 99/mm3, range 7 to 251, versus 384/mm3, range 171 to 724 in those without HIV infection, p = 0.007). Intracerebral mass lesions were more common in the HIV-infected group (60% versus 14% in the uninfected group, p = 0.01), although the presence of a mass did not correlate with focal neurologic deficits, altered level of consciousness, or mortality.
CONCLUSION: With the exception of an increased incidence of intracerebral mass lesions in HIV-infected individuals, HIV infection appears to have little impact on the findings and in-hospital mortality of tuberculous meningitis.

Entities:  

Mesh:

Year:  1992        PMID: 1442854     DOI: 10.1016/0002-9343(92)90579-z

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  34 in total

Review 1.  HTLV-1 and HIV infections of the central nervous system in tropical areas.

Authors:  P Cabre; D Smadja; A Cabié; C R Newton
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-05       Impact factor: 10.154

Review 2.  Tuberculous meningitis.

Authors:  G Thwaites; T T Chau; N T Mai; F Drobniewski; K McAdam; J Farrar
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-03       Impact factor: 10.154

Review 3.  Central nervous system infection during immunosuppression.

Authors:  Joseph R Zunt
Journal:  Neurol Clin       Date:  2002-02       Impact factor: 3.806

4.  Comparative utility of cytokine levels and quantitative RD-1-specific T cell responses for rapid immunodiagnosis of tuberculous meningitis.

Authors:  Vinod B Patel; Ravesh Singh; Cathy Connolly; Victoria Kasprowicz; Thumbi Ndung'u; Keertan Dheda
Journal:  J Clin Microbiol       Date:  2011-08-31       Impact factor: 5.948

5.  Extraspinal tuberculous arthritis in HIV era.

Authors:  P Lertsrisatit; K Nantiruj; K Totemchokchyakarn; S Janwityanujit
Journal:  Clin Rheumatol       Date:  2006-04-28       Impact factor: 2.980

6.  Gene Expression Profiling of Tuberculous Meningitis Co-infected with HIV.

Authors:  Ghantasala S Sameer Kumar; Abhilash K Venugopal; Manoj Kumar Kashyap; Rajesh Raju; Arivusudar Marimuthu; Shyam Mohan Palapetta; Yashwanth Subbanayya; Renu Goel; Ankit Chawla; Jyoti Bajpai Dikshit; Pramila Tata; H C Harsha; Jagadeesha Maharudraiah; Y L Ramachandra; Parthasarathy Satishchandra; T S Keshava Prasad; Akhilesh Pandey; Anita Mahadevan; S K Shankar
Journal:  J Proteomics Bioinform       Date:  2012-09-09

Review 7.  Quality of life in tuberculosis: a review of the English language literature.

Authors:  Betty Chang; Albert W Wu; Nadia N Hansel; Gregory B Diette
Journal:  Qual Life Res       Date:  2004-12       Impact factor: 4.147

Review 8.  Tuberculosis of the central nervous system.

Authors:  R K Garg
Journal:  Postgrad Med J       Date:  1999-03       Impact factor: 2.401

Review 9.  Multidrug-resistant tuberculous meningitis.

Authors:  Thomas F Byrd; Larry E Davis
Journal:  Curr Neurol Neurosci Rep       Date:  2007-11       Impact factor: 5.081

Review 10.  Tuberculosis and HIV disease: two decades of a dual epidemic.

Authors:  Muktar H Aliyu; Hamisu M Salihu
Journal:  Wien Klin Wochenschr       Date:  2003-10-31       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.